Skip to main content
. 2020 Apr 14;11(2):e03258-19. doi: 10.1128/mBio.03258-19

FIG 4.

FIG 4

Antimicrobial activity of AMPR-11 in the murine model of sepsis. (A) Cell viability assay of mammalian cells (HeLa cells, HEK293 cells, and HUVECs) with daptomycin, magainin 2, or AMPR-11. Peptides from 0 to 256 μg/ml were incubated for 2 h and analyzed by an MTT assay. (B) Hemolysis assay of RBCs incubated with daptomycin, magainin 2, melittin, or AMPR-11. The percentage of hemolyzed RBCs was analyzed by spectrophotometer. (C) Body weight changes of C57BL/6 mice after intravenous administration of AMPR-11 (100 mg/kg) or PBS. (D) Experimental workflow of the sepsis model. (E) Survival rates in mice infected with P. aeruginosa, S. aureus, K. pneumoniae, or A. baumannii. Each group was treated with PBS, imipenem (10 mg/kg with intraperitoneal administration, four times q12h), or AMPR-11 (10 mg/kg with intravenous administration, single dose). Survival rates were calculated with 15 mice/group for K. pneumoniae and A. baumannii and 20 mice/group for P. aeruginosa and S. aureus. (F) Numbers of bacteria in mouse blood after 48 h of bacterial infection with or without AMPR-11 administration. Data represent means ± the SD. **, P ≤ 0.05; ***, P ≤ 0.001 (by two-way ANOVA). DAP., daptomycin; MAG., magainin 2; IMIP.; imipenem.